Biodesix, Inc. BDSX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +209.56%
- 1 year
- +232.02%
- Market cap
- 222.10M
- Revenue (ttm)
- 65.56M
- Profit margin
- -66.84%
- EPS (ttm)
- -3.10
- Shares out
- 145.47M
- Forward P/E
- -6.64
- YTD return
- +209.56%
- 1-year return
- +232.02%
- Volume
- 38.78K
- Avg volume
- 104.41K
- Open
- 21.80
- Previous close
- 21.78
- Day's range
- 20.74 – 22.89
- 52-week range
- 5.26 – 31.97
- Beta
- 1.21
- Price target
- 3.10 (-85.3%)
2Y -7.06 (-25.40%)
Key statistics
- Enterprise value
- 259.96M
- PEG ratio
- 0.00
- Price / sales
- 3.24
- Price / book
- 7.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 34.50%
- Free cash flow
- -43.44M
- Total cash
- 31.41M
- Total debt
- 62.98M
- Return on equity
- -331.82%
- Short % of float
- 0.68%
- 50-day average
- 1.43
- 200-day average
- 1.53
Analyst view
- Target (low)
- 3.00
- Target (mean)
- 3.10
- Target (high)
- 3.50
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2024 | Scotiabank | init | — | Sector Outperform |
| Jul 26, 2024 | Craig-Hallum | init | — | Buy |
| May 13, 2024 | TD Cowen | init | — | Buy |
| May 3, 2024 | Lake Street | init | — | Buy |
| Mar 4, 2024 | Canaccord Genuity | reit | Buy | Buy |
| Dec 7, 2023 | Canaccord Genuity | reit | Buy | Buy |
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- biodesix.com
News
All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy 
Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know 
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 
Biodesix Announces That The American College Of Chest Physicians Has Published A New Framework For Clinical Practice, "Building A Lung Nodule Program: From Detection To Diagnosis." 
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification 
Biodesix Adds AI-Powered Imaging Test To Expand Lung Cancer Risk Screening 
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers 
TD Cowen Maintains Buy on Biodesix, Raises Price Target to $40 
Biodesix Announces Multiple Presentations At CHEST 2026 Highlighting How Nodify Lung Testing Is Being Incorporated Into Real-World Lung Nodule Management 
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
Your note
Sign in to keep a note on BDSX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COWIE ROBIN HARPER | Chief Financial Officer | Sale | Nov 11, 2024 | 203,336 |
| HUTTON SCOTT | Chief Executive Officer | Sale | Nov 11, 2024 | 532,979 |
| KENNEDY LAWRENCE T JR. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 20, 2024 | 0 |
| MASSARANY HANY | Director | Purchase | Nov 4, 2024 | 0 |
| O'KANE KIERAN | Officer | Sale | Nov 11, 2024 | 97,448 |
| PATIENCE JOHN | Chairman of the Board | Purchase | Nov 4, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Telemark Asset Management, LLC | 5.69% | 8,282,490 | 12.09M | Sep 29, 2024 |
| Wilmington Savings Fund Society, FSB | 4.19% | 6,095,034 | 8.90M | Sep 29, 2024 |
| AIGH Capital Management LLC | 3.90% | 5,679,812 | 8.29M | Sep 29, 2024 |
| Birchview Capital, LP | 3.81% | 5,541,176 | 8.09M | Sep 29, 2024 |
| Farallon Capital Management LLC | 3.19% | 4,636,791 | 6.77M | Sep 29, 2024 |
| Sio Capital Management, LLC | 2.98% | 4,338,514 | 6.33M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.99% | 1,436,112 | 2.10M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.98% | 1,418,674 | 2.07M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.28% | 411,862 | 601.32K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.19% | 276,311 | 403.41K | Sep 29, 2024 |
| 1290 Fds-1290 Essex Small Cap Growth Fd | 0.12% | 179,590 | 262.20K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 134,772 | 196.77K | Oct 30, 2024 |